

ONLINE-ONLY SUPPLEMENTARY MATERIAL

Supplementary Table 1. Syntax used through database searching on PubMed, Scopus and Web of Science.

PubMed <up to June 30, 2022>

| | | |
|----|---|----|
| #1 | "Metabolic dysfunction-associated fatty liver disease" AND "cardiovascular disease" | 35 |
| #2 | "MAFLD" AND "CVD" | 17 |
| #3 | "Metabolic dysfunction associated fatty liver disease" AND "mortality" | 33 |
| #4 | "MAFLD" AND "mortality" | 63 |


Scopus <up to June 30, 2022>

| | | |
|----|---|----|
| #1 | "Metabolic dysfunction-associated fatty liver disease" AND "cardiovascular disease" | 45 |
| #2 | "MAFLD" AND "CVD" | 16 |
| #3 | "Metabolic dysfunction-associated fatty liver disease" AND "mortality" | 37 |
| #4 | "MAFLD" AND "mortality" | 75 |





Web of Science <up to June 30, 2022>

| | | |
|----|---|----|
| #1 | "Metabolic dysfunction-associated fatty liver disease" AND "cardiovascular disease" | 45 |
| #2 | "MAFLD" AND "CVD" | 17 |
| #3 | "Metabolic dysfunction-associated fatty liver disease" AND "mortality" | 45 |
| #4 | "MAFLD" AND "mortality" | 80 |

Supplementary Figure 1. The PRISMA flow diagram for search and selection processes of the meta-analysis.



Supplementary Figure 2. Univariable metaregression analyses. A meta-analysis of the associations of body mass index and percentage of pre-existing type 2 diabetes mellitus at baseline with the risk of incident fatal and nonfatal cardiovascular events, by using either NAFLD (panels A and B) or MAFLD definitions (panels C and D).



Supplementary Figure 3. Funnel plot of standard error by log-hazard ratio for the risk of incident CVD events (for the 7 longitudinal cohort studies included in Figure 1). P-value by the Egger's regression test.

